Novavax (NASDAQ:NVAX - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter. Novavax has set its FY 2024 guidance at EPS.Parties interested in registering for the company's conference call can do so using this link.
Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.82 by ($0.83). The firm had revenue of $415.50 million during the quarter, compared to the consensus estimate of $458.57 million. Novavax's revenue for the quarter was down 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.58 earnings per share. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Novavax Stock Performance
Shares of NASDAQ:NVAX traded up $0.32 during midday trading on Tuesday, reaching $9.44. The company's stock had a trading volume of 3,476,405 shares, compared to its average volume of 9,859,992. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -3.42 and a beta of 2.10. The firm has a 50 day moving average price of $11.83 and a two-hundred day moving average price of $12.27. Novavax has a fifty-two week low of $3.53 and a fifty-two week high of $23.86.
Analyst Ratings Changes
A number of research firms recently weighed in on NVAX. B. Riley reaffirmed a "buy" rating and set a $26.00 price target (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Jefferies Financial Group dropped their price target on Novavax from $31.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, October 16th. Finally, JPMorgan Chase & Co. upped their price target on Novavax from $8.00 to $9.00 and gave the stock an "underweight" rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $17.83.
Read Our Latest Research Report on Novavax
About Novavax
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Stories
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
